←
ISARIC4C168 posts
ISARIC4C avatar

ISARIC4C

@CCPUKstudy

The ISARIC Coronovirus Clinical Characterisation Consortium is recruiting COVID-19 patients. Urgent public health research supported by @NIHRresearch @HPRUezi

◷ Joined February 2020▧ 4 Photos and videos
BESS avatar
⟳ ISARIC4C retweeted
BESS@BESStudy·26 Jun 2025

The results of the BESS trial will be announced at 14:40GMT today at the European Society of Paediatric and Neonatal Intensive Care, Alicante, Spain.

Post attachment
Professor Calum Semple OBE avatar
⟳ ISARIC4C retweeted
Professor Calum Semple OBE@ProfCalumSemple·30 Sep 2023

Timely collation, linkage and analysis of data has been key to informing the public health and clinical response in outbreaks of MERS, COVID-19, and Childhood Acute Severe Hepatitis of Unknown Origin @CCPUKstudy @ISARIC1 #DataSavesLives

I have laid out how sharing data improves direct patient care, NHS effectiveness and supports medical research gov.uk/government/speeches/u… The Information Commissioner, National Data Guardian and I have explained the benefits of clinical staff sharing data to support patient care.

Professor Chris Whitty avatar
⟳ ISARIC4C retweeted
Professor Chris Whitty@CMO_England·29 Sep 2023

I have laid out how sharing data improves direct patient care, NHS effectiveness and supports medical research gov.uk/government/speeches/u… The Information Commissioner, National Data Guardian and I have explained the benefits of clinical staff sharing data to support patient care.

This tweet is unavailable

Professor Calum Semple OBE avatar
⟳ ISARIC4C retweeted
Professor Calum Semple OBE@ProfCalumSemple·20 Sep 2023

In general, the impact of Covid-19 on causing critical illness, i.e needing intensive care, in children lessened over the first two years of the pandemic, including when the omicron variant became dominant @CCPUKstudy @ISARIC1

Researchers from @livuni have contributed to a paediatric study that provides valuable insights into the impact of Covid-19 on hospitalised children during the pandemic. Read more here news.liverpool.ac.uk/2023/09… @ProfCalumSemple

Post attachment
Jeremy Farrar avatar
⟳ ISARIC4C retweeted
Jeremy Farrar@JeremyFarrar·25 Aug 2023

Yes, along with loss of biodiversity, changing habitats of animals, illegal wild life trade, urbanisation, trade and travel. All key drivers more frequent & complex epidemics & pandemics. The epidemic events are symptoms of our changing world & need to address the key drivers

Antonia Ho avatar
⟳ ISARIC4C retweeted
Antonia Ho@DrToniHo·30 Mar 2023

TL;DR: Our preprint was 1ST to report association btwn #AAV2 & hepatitis cases, found on metagenomic sequencing in 9/9 early 🏴󠁧󠁢󠁳󠁣󠁴󠁿cases vs 0/58 controls. #adenovirus found in 6/9 cases. Cases also >likely to carry HLA DRB1*04:01 allele (8/9; 89%) vs 🏴󠁧󠁢󠁳󠁣󠁴󠁿blood donors (16%) 2/

Post attachment
ISARIC4C avatar
ISARIC4C@CCPUKstudy·30 Mar 2023

Doctors, scientists, & public health teams are working together, learning lessons from their responses to past outbreaks pandemics. This new way of working has led to the rapid discovery of the cause of this mystery disease @ISARIC1 @kennethbaillie @ProfCalumSemple

🌟Proud to share our paper 'Adeno-associated virus 2 infection in children with non-A-E hepatitis', out in @Nature today!🌟 nature.com/articles/s41586-0… @CVRinfo @UofGlasgow @P_H_S_Official @RHCGlasgow @CCPUKstudy A🧵highlighting key updates from preprint released in July 2022 1/

Antonia Ho avatar
⟳ ISARIC4C retweeted
Antonia Ho@DrToniHo·25 Jul 2022

Cases (n=9): - admitted 14 March-4 April 22 - recruited to @CCPUKstudy - 4 male; median age 3.9 (IQR 3.4-5.1) - most had GI symptoms 1-11 wks b4 hepatitis - no immunocompromise - none had covid 💉 - Hep A-E, EBV/CMV, HHV6/7, HSV, autoantibodies neg - no transplants/ deaths 2/

Post attachment
Antonia Ho avatar
⟳ ISARIC4C retweeted
Antonia Ho@DrToniHo·12 Aug 2022

Timely release of our latest @CCPUKstudy study, led by @LanceTurtle, evaluating impact of #immunocompromise (IC) on outcome in hospitalised #COVID19. TL;DR: Despite effective 💉& Rx, IC individuals remain at ⬆️ risk of death from COVID19 compared to immunoconpetent persons.

Today there is a lot of coverage of immune compromised people and whether the antibody treatment #Evusheld would benefit this population. Of relevance to this, is our latest pre-print on COVID-19 in hospitalised immune compromised people. @evusheld4theuk medrxiv.org/cgi/content/shor…